Evidence map›Paper›PMID 30078070›Full record

Trial reportJournal of neuro-oncology2018

Neurocognitive evaluation of brain metastases patients treated with post-resection stereotactic radiosurgery: a prospective single arm clinical trial.

Assaf Berger, Ido Strauss, Shlomit Ben Moshe, Benjamin W Corn, Dror Limon, Nathan Shtraus, Tal Shahar, Andrew A Kanner

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Neurological and Medical Complications in Brain Tumor Patients.Current neurology and neuroscience reports · 2020
    Review
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Assaf BergerDepartment of Neurosurgery, Tel Aviv Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel. assaf.berger@gmail.com.ORCID http://orcid.org/0000-0003-1198-2807
Ido StraussDepartment of Neurosurgery, Tel Aviv Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
Shlomit Ben MosheDepartment of Neurosurgery, Tel Aviv Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
Benjamin W CornInstitute of Radiotherapy, Tel Aviv Medical Center, Tel Aviv, Israel.
Dror LimonInstitute of Radiotherapy, Tel Aviv Medical Center, Tel Aviv, Israel.
Nathan ShtrausInstitute of Radiotherapy, Tel Aviv Medical Center, Tel Aviv, Israel.
Tal ShaharDepartment of Neurosurgery, Shaare Zedek Medical Center, Jerusalem, Israel.
Andrew A KannerDepartment of Neurosurgery and Stereotactic Radiosurgery Unit, Rabin Medical Center, Petah Tikva, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePost-operative radiation therapy for brain metastases (BM) has become standard treatment. Concerns regarding the deleterious cognitive effects of Whole Brain Radiation Therapy spurred a trend to use focal therapies such as stereotactic radiosurgery (SRS). The purpose of this study was to prospectively evaluate the neuropsychological effects following post-resection SRS treatment since limited data exist in this context.

methodsWe conducted a prospective single arm cohort study of patients with 1-2 BM, who underwent resection of a single BM between May 2015 to December 2016. Patients were evaluated for cognitive functions (NeuroTrax computerized neuropsychological battery; Modiin, Israel) and quality of life (QOL; QLQ-30, QLQ-BN20) before and 3 months following post-resection SRS.

resultsTwelve out of 14 patients completed pre- and post-SRS neurocognitive assessments. Overall, we did not detect significant neurocognitive or QOL changes 3 months following SRS. In a subgroup analysis among patients younger than 60 years, median global cognitive score increased from a pre-treatment score of 88 (72-102) to 95 (79-108), 3 months following SRS treatment, p = 0.042; Wilcoxon paired non-parametric test. Immediate verbal memory and executive functions scores increased from 86 (72-98) to 98 (92-112) and 86 (60-101) to 100 (80-126), respectively, p = 0.043. No significant cognitive changes were discovered among patients at the age of 60 or older.

conclusionsPost-resection radiosurgery has a safe neuro-cognitive profile and is associated with preservation of nearly all quality of life parameters. Patients younger than 60 years benefit most and may even regain some cognitive functions within a few months after treatment.

Indexed as

CognitionNeurosurgical ProceduresRadiosurgeryAdultAgedAged, 80 and overBrain NeoplasmsCombined Modality TherapyFemaleHumansMaleMiddle AgedNeuropsychological TestsQuality of LifeTreatment OutcomeBrain metastasesCognitionQuality of lifeStereotactic radiosurgery

Identifiers

PMID30078070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.